10-K: Precigen's 2023 Annual Report: Focus on Gene and Cell Therapies Amidst Financial Challenges

Precigen's 2023 annual report highlights its advancements in gene and cell therapies while acknowledging substantial doubt about its ability to continue as a going concern due to ongoing losses.

Summary

• Precigen is a biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
• The company leverages proprietary technology platforms like UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics.
• Key clinical programs include PRGN-3005, PRGN-3006, PRGN-3007 (UltraCAR-T), and PRGN-2009, PRGN-2012 (AdenoVerse).
• The company has completed a Phase 1b/2a study of AG019 (ActoBiotics).
• Precigen has developed an electroporation device, UltraPorator, for rapid and cost-effective manufacturing of UltraCAR-T therapies.
• The company reported a net loss of $95.9 million for 2023, with an accumulated deficit of $2.0 billion.
• There is substantial doubt about the company's ability to continue as a going concern due to its financial position.
• The company's ability to fund operations depends on raising additional capital through various means.
• Research and development expenses were $48.6 million in 2023.
• The company is preparing for a potential launch of PRGN-2012 in 2025, pending regulatory approval.

Sentiment

Score: 4

Explanation: The document highlights promising clinical advancements and novel technology platforms, but the significant financial losses and going concern warning temper the overall sentiment. The company faces substantial financial risks and challenges in commercialization.

Positives

• The company has a diverse portfolio of proprietary technology platforms.
• The company has a robust pipeline of preclinical programs.
• The company has internal cGMP manufacturing capabilities for AdenoVerse-based therapeutics.
• The company has received Breakthrough Therapy Designation and Orphan Drug designation for PRGN-2012 by the FDA.
• The company has received Orphan Drug Designation for PRGN-2012 from the European Commission.
• PRGN-3006 has been granted Orphan Drug designation in patients with AML and Fast Track Designation in patients with r/r AML by the FDA.

Negatives

• The company has a history of net losses and an accumulated deficit of $2.0 billion.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not achieve or maintain profitability.
• The company will need substantial additional capital in the future to fund its business.
• The company has limited experience designing and implementing clinical trials.
• The company has never commercialized a product and has no active sales force.
• The company may lack the necessary expertise, personnel, and resources to successfully commercialize its product candidates.
• The company's stock price is volatile, and purchasers of its common stock could incur substantial losses.
• The company does not anticipate paying cash dividends.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's product candidates may not receive regulatory approval or achieve market acceptance.
• Clinical trials may be delayed or terminated due to various factors.
• The company may rely on third parties for development and commercialization of product candidates.
• The company may be sued for product liability.
• The company may be subject to anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• The company may experience a significant breach of data security or disruption in its information systems.
• The company may pursue strategic acquisitions and investments that could have an adverse impact on its business.
• The company's ability to use net operating loss carryforwards may be limited.
• The company's ability to compete may decline if it does not adequately protect its intellectual property rights.

Future Outlook

The company plans to submit a BLA for PRGN-2012 under an accelerated approval pathway in the second half of 2024 and is preparing for a potential launch in 2025. The company expects to continue to advance its clinical and preclinical programs and may enter into strategic transactions.

Management Comments

• The company is focused on advancing its clinical programs with the goal of improving outcomes for patients with significant unmet medical needs.
• The company is exercising discipline in its portfolio management by systematically evaluating data from its preclinical programs to make rapid go/no-go decisions.
• The company is seeking strategic partnerships to maximize value generation.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, facing competition from companies developing similar gene and cell therapies, as well as traditional cancer treatments. The company's focus on precision medicine and novel technology platforms aims to differentiate it from competitors.

Comparison to Industry Standards

• The company's UltraCAR-T platform aims to address the shortcomings of current CAR-T therapies by reducing manufacturing time and costs, and improving outcomes.
• Competitors in the CAR-T space include Bristol-Myers Squibb, Kite, Amgen, and others, who are developing treatments for similar indications.
• The company's AdenoVerse platform, particularly its gorilla adenovectors, is designed to overcome limitations of standard human adenovectors.
• Competitors in the HPV-associated cancer immunotherapy space include INOVIO Pharmaceuticals, BioNTech SE, and others.
• The company's ActoBiotics platform is a unique approach to delivering therapeutic proteins and peptides at mucosal sites.
• Competitors in the T1D immunotherapy space include Sanofi, Midatech Pharma, and MerciaPharma.

Corporate Governance

Legal Proceedings

• The company is involved in litigation and legal matters, including governmental investigations.
• The company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on its business, financial condition, results of operations, or cash flows.

Related Party Transactions

• The company has engaged in transactions with companies in which Randal J. Kirk, its Executive Chairman, and his affiliates have an interest.
• In January 2023, related parties and their affiliates purchased 11,517,712 shares of common stock in a public offering.

Stakeholder Impact

• Shareholders face the risk of substantial losses due to the company's volatile stock price and financial challenges.
• Employees may be affected by potential delays or reductions in operations due to financial constraints.
• Patients may benefit from the company's advancements in gene and cell therapies, but the company's financial instability could impact the availability of these treatments.
• The company's suppliers and creditors may be affected by the company's financial challenges and potential delays in payments.

Next Steps

• The company plans to submit a BLA for PRGN-2012 under an accelerated approval pathway in the second half of 2024.
• The company is preparing for a potential launch of PRGN-2012 in 2025.
• The company will continue to advance its clinical and preclinical programs.
• The company will continue to evaluate internal and external strategies to support cGMP manufacturing needs of its AdenoVerse-based therapeutics.

Key Dates

Keywords

gene therapy, cell therapy, immunotherapy, UltraCAR-T, AdenoVerse, ActoBiotics, oncology, autoimmune disorders, infectious diseases, clinical trials, biopharmaceutical, RRP, AML, MDS, ROR1, HPV, manufacturing, FDA, regulatory approval, financial risk